Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberta Valenti

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Cancer Research|April 6, 2007
Tumor-released microvesicles as vehicles of immunosuppressionRoberta Valenti, Veronica Huber, Manuela Iero, et al.
Expert Review of Anticancer Therapy|August 24, 2006
Vaccination: role in metastatic melanomaLorenzo Pilla, Roberta Valenti, Andrea Marrari, et al.
Social Science & Medicine (1982)|December 13, 2025
Beyond Preferences: Rethinking shared decision-making through the Lens of careMauro Turrini, Roberta Valenti, Jeanette Bresson Ladegaard Knox, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2004
Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigensDiego Tosi, Roberta Valenti, Agata Cova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccinePaola Filipazzi, Roberta Valenti, Veronica Huber, et al.
Cancer Research|September 20, 2006
Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytesRoberta Valenti, Veronica Huber, Paola Filipazzi, et al.
European Journal of Cancer (Oxford, England : 1990)|May 10, 2021
Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET studyDiana Lüftner, Hans Tesch, Marcus Schmidt, et al.
Expert Opinion on Biological Therapy|June 7, 2005
Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?Licia Rivoltini, Paola Canese, Veronica Huber, et al.
Gastroenterology|June 9, 2005
Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escapeVeronica Huber, Stefano Fais, Manuela Iero, et al.
Breast Care (Basel, Switzerland)|February 22, 2024
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR StudyNadia Harbeck, Denise Wrobel, Matthias Zaiss, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Cancer Research|April 6, 2007
Tumor-released microvesicles as vehicles of immunosuppressionRoberta Valenti, Veronica Huber, Manuela Iero, et al.
Expert Review of Anticancer Therapy|August 24, 2006
Vaccination: role in metastatic melanomaLorenzo Pilla, Roberta Valenti, Andrea Marrari, et al.
Social Science & Medicine (1982)|December 13, 2025
Beyond Preferences: Rethinking shared decision-making through the Lens of careMauro Turrini, Roberta Valenti, Jeanette Bresson Ladegaard Knox, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2004
Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigensDiego Tosi, Roberta Valenti, Agata Cova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccinePaola Filipazzi, Roberta Valenti, Veronica Huber, et al.
Cancer Research|September 20, 2006
Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytesRoberta Valenti, Veronica Huber, Paola Filipazzi, et al.
European Journal of Cancer (Oxford, England : 1990)|May 10, 2021
Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET studyDiana Lüftner, Hans Tesch, Marcus Schmidt, et al.
Expert Opinion on Biological Therapy|June 7, 2005
Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?Licia Rivoltini, Paola Canese, Veronica Huber, et al.
Gastroenterology|June 9, 2005
Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escapeVeronica Huber, Stefano Fais, Manuela Iero, et al.
Breast Care (Basel, Switzerland)|February 22, 2024
Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR StudyNadia Harbeck, Denise Wrobel, Matthias Zaiss, et al.
Pageof 2